310 related articles for article (PubMed ID: 16210627)
1. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand.
Carr WH; Pando MJ; Parham P
J Immunol; 2005 Oct; 175(8):5222-9. PubMed ID: 16210627
[TBL] [Abstract][Full Text] [Related]
2. Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B.
Thananchai H; Gillespie G; Martin MP; Bashirova A; Yawata N; Yawata M; Easterbrook P; McVicar DW; Maenaka K; Parham P; Carrington M; Dong T; Rowland-Jones S
J Immunol; 2007 Jan; 178(1):33-7. PubMed ID: 17182537
[TBL] [Abstract][Full Text] [Related]
3. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells.
O'Connor GM; Guinan KJ; Cunningham RT; Middleton D; Parham P; Gardiner CM
J Immunol; 2007 Jan; 178(1):235-41. PubMed ID: 17182560
[TBL] [Abstract][Full Text] [Related]
4. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402.
Sharma D; Bastard K; Guethlein LA; Norman PJ; Yawata N; Yawata M; Pando M; Thananchai H; Dong T; Rowland-Jones S; Brodsky FM; Parham P
J Immunol; 2009 Oct; 183(7):4569-82. PubMed ID: 19752231
[TBL] [Abstract][Full Text] [Related]
5. Putative role of KIR3DL1/3DS1 alleles and HLA-Bw4 ligands with end stage renal disease and long term renal allograft survival.
Prakash S; Sarangi AN; Alam S; Sonawane A; Sharma RK; Agrawal S
Gene; 2017 Dec; 637():219-229. PubMed ID: 28942035
[TBL] [Abstract][Full Text] [Related]
6. HLA alleles determine differences in human natural killer cell responsiveness and potency.
Kim S; Sunwoo JB; Yang L; Choi T; Song YJ; French AR; Vlahiotis A; Piccirillo JF; Cella M; Colonna M; Mohanakumar T; Hsu KC; Dupont B; Yokoyama WM
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3053-8. PubMed ID: 18287063
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory natural killer cell receptor KIR3DL1 with its ligand Bw4 constraints HIV-1 disease among South Indians.
Maruthamuthu S; Rajalingam R; Pandian K; Madasamy S; Manoharan M; Pitchai L; Murugesan A; Mariakuttikan J
AIDS; 2018 Nov; 32(18):2679-2688. PubMed ID: 30289808
[TBL] [Abstract][Full Text] [Related]
8. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function.
Yawata M; Yawata N; Draghi M; Little AM; Partheniou F; Parham P
J Exp Med; 2006 Mar; 203(3):633-45. PubMed ID: 16533882
[TBL] [Abstract][Full Text] [Related]
9. KIR3DL01 recognition of Bw4 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and Old World monkeys.
Schafer JL; Colantonio AD; Neidermyer WJ; Dudley DM; Connole M; O'Connor DH; Evans DT
J Immunol; 2014 Feb; 192(4):1907-17. PubMed ID: 24453246
[TBL] [Abstract][Full Text] [Related]
10. The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1.
Pando MJ; Gardiner CM; Gleimer M; McQueen KL; Parham P
J Immunol; 2003 Dec; 171(12):6640-9. PubMed ID: 14662867
[TBL] [Abstract][Full Text] [Related]
11. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
Bakker AB; Phillips JH; Figdor CG; Lanier LL
J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
[TBL] [Abstract][Full Text] [Related]
12. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.
Yusa S; Catina TL; Campbell KS
J Immunol; 2002 May; 168(10):5047-57. PubMed ID: 11994457
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals.
Naumova E; Mihaylova A; Stoitchkov K; Ivanova M; Quin L; Toneva M
Cancer Immunol Immunother; 2005 Feb; 54(2):172-8. PubMed ID: 15248031
[TBL] [Abstract][Full Text] [Related]
14. Multiple transcripts of the killer cell immunoglobulin-like receptor family, KIR3DL1 (NKB1), are expressed by natural killer cells of a single individual.
Vyas Y; Selvakumar A; Steffens U; Dupont B
Tissue Antigens; 1998 Dec; 52(6):510-9. PubMed ID: 9894849
[TBL] [Abstract][Full Text] [Related]
15. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
Thöns C; Senff T; Hydes TJ; Manser AR; Heinemann FM; Heinold A; Heilmann M; Kim AY; Uhrberg M; Scherbaum N; Lauer GM; Khakoo SI; Timm J
J Hepatol; 2017 Sep; 67(3):462-470. PubMed ID: 28412292
[TBL] [Abstract][Full Text] [Related]
16. KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.
Forlenza CJ; Boudreau JE; Zheng J; Le Luduec JB; Chamberlain E; Heller G; Cheung NK; Hsu KC
J Clin Oncol; 2016 Jul; 34(21):2443-51. PubMed ID: 27069083
[TBL] [Abstract][Full Text] [Related]
17. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
18. The Role of the HLA Class I α2 Helix in Determining Ligand Hierarchy for the Killer Cell Ig-like Receptor 3DL1.
Saunders PM; MacLachlan BJ; Widjaja J; Wong SC; Oates CVL; Rossjohn J; Vivian JP; Brooks AG
J Immunol; 2021 Feb; 206(4):849-860. PubMed ID: 33441440
[TBL] [Abstract][Full Text] [Related]
19. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis.
Karlsen TH; Boberg KM; Olsson M; Sun JY; Senitzer D; Bergquist A; Schrumpf E; Thorsby E; Lie BA
J Hepatol; 2007 May; 46(5):899-906. PubMed ID: 17383044
[TBL] [Abstract][Full Text] [Related]
20. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.
Martin MP; Qi Y; Gao X; Yamada E; Martin JN; Pereyra F; Colombo S; Brown EE; Shupert WL; Phair J; Goedert JJ; Buchbinder S; Kirk GD; Telenti A; Connors M; O'Brien SJ; Walker BD; Parham P; Deeks SG; McVicar DW; Carrington M
Nat Genet; 2007 Jun; 39(6):733-40. PubMed ID: 17496894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
